Phase III Trial to Examine Veliparib in BRCA Positive Breast CancerApril 19th 2017
An ongoing trial is evaluating the addition of PARP inhibitor velaparib to a chemotherapy combination, for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.
Fast Facts for the Frontline: Oral Care and Mucositis During Cancer TreatmentApril 12th 2017
Many anticancer therapies increase the risk of oral mucositis, leading to dose reduction or treatment delays. There are interventions that can help, and more are under study.